Clinical research on brain natriuretic peptide guiding the application of β1 receptor blocker in patients with moderate to severe heart failure

Acta Cardiologica Sinica

Volumn 31, Issue 1, 2015, Pages 52-58

  Li, Jiang Jin ^a   Xiang, Xiao Li ^a   Tian, Xiao Yi ^a   Shi, Ya Fei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

BNP; Heart failure; receptor blocker

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; LANATOSIDE C; LOOP DIURETIC AGENT; METOPROLOL SUCCINATE; MILRINONE; NITRIC ACID DERIVATIVE; NITROPRUSSIDE SODIUM; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL RESEARCH; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOFLUORESCENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK;

EID: 84923043425     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: 10.6515/ACS20140728A     Document Type: Article

References (22)

1. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009;53:557-73.
2. Dobrek Ł, Thor P. Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy. Acta Pol Pharm 2011;68:307-16.
3. Aleksandrova EB, Sidorenko BA. Brain natriuretic peptide for early diagnosis of chronic heart failure in patients with preserved left ventricular ejection fraction. Kardiologiia 2012;52:27-32.
4. Shaikh K, Hanif B, Siddique AA, et al. Pro-brain natriuretic peptide plasma levels, left ventricular dimensions and ejection fraction in acute dyspnoea. J Coll Physicians Surg Pak 2012;22:751-5.
5. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type-natriuretic peptide predict death and cardiac events in patients with heart failure: a systematic review. BMJ 2005;330:625.
6. Bayés-Genís A, Lopez L, Zapico E, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail 2005;11:S3-8.
7. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001;7:21-9.
8. Valle R, Aspromonte N. Use of brain natriuretic peptide and bioimpedance to guide therapy in heart failure patients. Contrib Nephrol 2010;164:209-16.
9. Newton PJ, Betihavas V, Macdonald P. The role of b-type natriuretic peptide in heart failure management. Aust Crit Care 2009;22:117-23.
10. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of aminoterminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58:1881-9.
11. Kelly NP, Januzzi JL Jr. The role of B-type natriuretic peptide testing in guiding outpatient heart failure treatment. Curr Treat Options Cardiovasc Med 2013;15:397-409.
12. DeBeradinis B, Januzzi JL Jr. Use of biomarkers to guide outpatient therapy of heart failure. Curr Opin Cardiol 2012;27:661-8.
13. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
14. Packer M, Fowler M, Rouleau J, et al. COPERNICUS (carvedilol prospective randomized cumulative survival trial). A multicenter randomized double-blind, placebo-controlled study to determine the effect of carvedilol on mortality in severe congestive heart failure. Cardilvasc Drugs Ther 1999;13:2.
15. GattisWA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43:1534-41.
16. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
17. Knebel F, Schimke I, Pliet K, et al. BNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 2005;11:S38-41.
18. Michtalik HJ. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol 2011;107:1191-5.
19. Peacock WF, Soto KM. Current techniques of fluid status assessment. Contrib Nephrol 2010;164:128-42.
20. Valle R, Aspromonte N, Milani L, et al. Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Fail Rev 2011;16:519-29.
21. Wong DT, George K, Wilson J, et al. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure. Am J Cardiol 2011;107:573-8.
22. Saremi A, Gopal D, Maisel AS. Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure. Expert Rev Cardiovasc Ther 2012;10:191-203.